PL EN


Preferences help
enabled [disable] Abstract
Number of results
2006 | 53 | 4 | 801-805
Article title

Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model

Content
Title variants
Languages of publication
EN
Abstracts
EN
Vasculature targeting agents have been tested as cancer therapeutics for the past few years. Such therapy could be accomplished using, for example, bifunctional (two-domain) peptides. RGD-4C-GG-D(KLAKLAK)2, a peptide designed by Ellerby and coworkers (1999) (full sequence: ACDCRGDCFCGGKLAKLAKKLAKLAK), binds selectively to αVβ3 integrin receptors expressed in tumor neovasculature and, after internalization, effectively induces apoptosis of endothelial cells. The aim of this study was to examine if RGD-4C-GG-D(KLAKLAK)2 would efficiently target cells, among them B16(F10), that overexpress αVβ3 receptors, and whether it would be suitable for therapeutic treatment of primary B16(F10) murine melanoma tumors. Thus, the peptide would target two distinct tumor compartments: that formed by endothelium of blood vessels and that made up of neoplastic cells. The therapeutic peptide was recognized and did induce apoptosis in B16(F10) cell line. Tumor growth inhibition was observed following direct intratumoral administration. However, cessation of peptide administration led to rapid tumor growth and death of the animals.
Year
Volume
53
Issue
4
Pages
801-805
Physical description
Dates
published
2006
received
2006-06-29
revised
2006-10-12
accepted
2006-11-23
(unknown)
2006-12-01
References
  • Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
  • Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271: 58-65.
  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
  • Kamysz W, Okroj M, Lukasiak J (2003) Novel properties of antimicrobial peptides. Acta Biochim Polon 50: 461-469.
  • Line BR, Mitra A, Nan A, Ghandehari H (2005) Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 46: 1552-1560.
  • Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR (2005) Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 102: 191-201.
  • Mitrus I, Delic K, Wrobel N, Missol-Kolka E, Szala S (2006) Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice. Acta Biochim Polon 53: 357-360.
  • Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5: 436-446.
  • Szala S (2004) Two-domain vascular disruptive agents in cancer therapy. Curr Cancer Drug Targets 4: 501-509.
  • Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427.
  • Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
  • Zitzmann S, Ehemann V, Schwab M (2002) Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 62: 5139-5143.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv53p801kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.